Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NBTY Sales Increase 12% To $155 Mil. In Third Quarter

This article was originally published in The Tan Sheet

Executive Summary

NBTY sales rose 11.6% to $155.1 mil. in the third quarter ended June 30, but net income fell by nearly half, down 46.7% to $4.3 mil., from $8.1 mil. the year before. In the nine months, sales increased 8.9% to $463.7 mil., and net income dropped 53.9% to $4.3 mil. NBTY's bottom line was negatively affected by $4.6 mil. in litigation expenses related to the outcome of a dispute over the acquisition of Holland & Barrett, NBTY announced Aug. 5.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090172

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel